Investment
Features
FeesSafety
Academy
More
Pluang+

Compare D Wave Quantum Inc (QBTS) vs Viatris Inc (VTRS) Price & Performance

D Wave Quantum IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

D Wave Quantum Inc vs Viatris Inc — how do they compare? D Wave Quantum Inc trades at $14.38 (market cap $5.54B), while Viatris Inc trades at $17.63 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.6× D Wave Quantum Inc's market cap, and Viatris Inc pays a 2.75% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D Wave Quantum Inc for 32 Days and Viatris Inc for 57 Days on average.

QBTSVTRS
Market Cap
$5.54B$20.03B
Volume
16,671,45214,109,977
Sector
TechnologyHealth
52-Week High
$44.78$18.27
52-Week Low
$12.98$9.74
Typical Hold Time
32 Days57 Days
Enterprise Value
$5.04B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

D Wave Quantum Inc

D-Wave Quantum (QBTS) trades at $14.42, down 5.26% today, amid bearish technical signals and ongoing legal investigations. The company shows severe financial stress with a -2,001.59% net income margin and -$355M net loss in 2025, though it maintains a 64.19% gross margin. Revenue declined from $25M to $12M year-over-year, while cash flow turned negative in 2026. Despite 100% analyst buy ratings with a $34.38 consensus target, multiple law firms are investigating potential securities law violations.

The stock faces significant fundamental challenges with massive losses and declining revenue, offset by strong analyst optimism about quantum computing potential. Key risks include ongoing legal probes, cash burn acceleration, and competitive pressures in the emerging quantum sector. The current price sits 58% below analyst targets, creating potential upside if execution improves, but substantial operational turnaround is needed.

Viatris Inc

Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.

The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

QBTS
91% Buy9% Sell
Avg holding period · 32 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About D Wave Quantum Inc

D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.

Read more on QBTS →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →